Clinical trials: Bipolar Disorder 1
Bipolar I Disorder
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
- Trial name
- NCT00721955
- Testing
- Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
- Where
- 6 sites in United States
- Volunteers
- 314 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Bipolar Disorder, Substance Dependence
Modifying Group Therapy for Bipolar Substance Abusers - 1
The purpose of this study is to modify Integrated Group Therapy (IGT), which is has been found successful for patients with bipolar disorder (BD) and substance use disorder(SUD), so that it can be more readily adopted by…
- Trial name
- NCT00227838
- Testing
- Behavior Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Bipolar 1 Disorder, Schizophrenia Disorder
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
- Trial name
- NCT07744113
- Testing
- OLZ/SAM
- Where
- United States
- Sponsor
- Alkermes, Inc.
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder (BD), Bipolar 1 Depression
Neuromodulation of Mood Switch Circuitry in Bipolar Disorder
This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood…
- Conditions
- Bipolar Disorder (BD), Bipolar 1 Depression, rTMS, fMRI
- Trial name
- CircuitBD (NCT07680153)
- Testing
- MagVenture MagPro TMS system
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Weill Medical College of Cornell University
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
- Trial name
- NCT00080314
- Testing
- Aripiprazole
- Where
- 28 sites in United States
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder
Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting
Bipolar I Disorder (BP1)is a severe chronic mood disorder characterized by manic and depression. BP1 has high probability of being misunderstood as unipolar major depressive disorder (MDD).
- Trial name
- NCT05956483
- Where
- 9 sites in United States
- Volunteers
- 423 people
- Sponsor
- AbbVie
Bipolar Disorder, Cocaine Dependence
Citicoline for Bipolar 1 Disorder and Cocaine Dependence
A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial of citicoline as an add-on therapy will be conducted in 200 outpatients with bipolar I disorder and cocaine dependence.
- Trial name
- NCT00619723
- Testing
- Citicoline, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar 1 Disorder
Risperidone vs Cariprazine in Acute Mania
Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks.
- Trial name
- RCAM (NCT07665073)
- Testing
- Risperidone, Cariprazine
- Volunteers
- 50 people
- Sponsor
- Pakistan Institute of Medical Sciences
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Major Depressive Episode (MDE), Unipolar Disorder
Evaluating the Therapeutic Potential of Focal Electrically Administered Seizure Therapy (FEAST) in the Treatment of Depression: A Multicenter Randomized Clinical Trial
A significant proportion of patients remain resistant to antidepressant therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant…
- Conditions
- Major Depressive Episode (MDE), Unipolar Disorder, Bipolar 1 Disorder
- Trial name
- FEAST-AFT (NCT07857122)
- Testing
- Stimulation by the Sigma ECT/FEAST device, Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL), Stimulation by Sigmastim ECT 200J device administered in bilateral (BT)
- Where
- 5 sites in France, Monaco
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier St Anne
Bipolar 1 Disorder, Schizophrenia
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated…
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT01981811
- Testing
- Aripiprazole, Ingestible Event Marker (IEM)
- Where
- 12 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes
The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.
- Trial name
- NCT00132678
- Testing
- Risperdal Consta
- Where
- 51 sites in United States, Austria and 8 more
- Volunteers
- 559 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar I Disorder
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following…
- Trial name
- NCT04030143
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation,Psychomotor
Outcomes of Antipsychotic Medication Used in the Emergency Department
To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.
- Trial name
- OAMED (NCT02504450)
- Testing
- Adasuve, Alternative medications
- Volunteers
- 93 people
- Sponsor
- Wake Forest University Health Sciences
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation, Schizophrenia
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
This is a single-arm pilot study to examine the impact of BXCL501 (sublingual film formulation of dexmedetomidine) administration on reducing the severity of undifferentiated acute agitation in patients presenting to the…
- Conditions
- Agitation, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05974527
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Sponsor
- Brigham and Women's Hospital
Bipolar Disorder
DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder
A phase 4 unequal randomization, double blind study to evaluate the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an Open label and long term maintenance treatment in children…
- Trial name
- NCT02623504
- Testing
- Carbamazepine
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Validus Pharmaceuticals
Major Depressive Disorder, Unipolar Depression
RTMS Feasibility Study on Adolescent Depression Stimulation
This is an open-label study, in which all participants receives an active treatment with repetitive transcranial magnetic stimulation (rTMS) according to clinical protocol.
- Conditions
- Major Depressive Disorder, Unipolar Depression, Bipolar Depression
- Trial name
- NCT06126198
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University